JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 523.00
-11.00 (-2.06%)
Oct 23, 2026, 3:30 PM JST
JCR Pharmaceuticals Revenue
JCR Pharmaceuticals had revenue of 9.70B JPY in the quarter ending June 30, 2026, with 13.20% growth. This brings the company's total for the last twelve months to 41.45B, up 23.75% year-over-year. In the fiscal year ending March 31, 2026, JCR Pharmaceuticals had annual revenue of 40.32B with 21.91% growth. That makes JCR Pharmaceuticals the 15,423rd largest company in the world by revenue and 1,661st in Japan.
Revenue (ttm)
41.45B
Revenue Growth
+23.75%
P/S Ratio
1.54
Revenue / Employee
42.08M
Employees
985
Market Cap
63.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 40.32B | 7.25B | 21.91% |
| Mar 31, 2025 | 33.07B | -9.80B | -22.86% |
| Mar 31, 2024 | 42.87B | 8.53B | 24.83% |
| Mar 31, 2023 | 34.34B | -16.74B | -32.77% |
| Mar 31, 2022 | 51.08B | 21.00B | 69.79% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Otsuka Holdings | 2.62T |
| Chugai Pharmaceutical | 1.34T |
| HOYA Corporation | 983.64B |
| KYORIN Pharmaceutical | 125.68B |
| ASKA Pharmaceutical Holdings | 70.87B |
| Medley | 41.00B |
| Shin Nippon Biomedical Laboratories | 33.92B |
JCR Pharmaceuticals News
- 11 days ago - JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome - Business Wire
- 23 days ago - Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America - Business Wire
- 27 days ago - JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy - Business Wire
- 6 weeks ago - MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB - Business Wire
- 3 months ago - JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome - Business Wire
- 4 months ago - JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 4 months ago - JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders - Business Wire
- 5 months ago - JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 - Business Wire